Video

Can Biosimilars Reduce Specialty Spending?

Author(s):

Davy James, Managing Editor

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Asthma COPD Breath Nebulizer And Mask Given By Doctor Or Nurse - Image credit: Angelov | stock.adobe.com
Psychiatric pharmacist and patient -- Image credit: NanSan | stock.adobe.com
Psychiatric pharmacist -- Image credit: HBS | stock.adobe.com
Hematology -- Image credit: DIgilife | stock.adobe.com
Image credit: Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Related Content
Study Highlights Filgrastim Savings Potential With Biosimilars
July 18th 2025

Study Highlights Filgrastim Savings Potential With Biosimilars

Ethan Nolin-Halpern, PharmD Candidate
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Patient with itchy hives (CSU) -- Image credit: wisely | stock.adobe.com
July 16th 2025

Follow-Up Study Confirms Omlyclo Biosimilarity to Xolair in Treatment of CSU

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
ATOPP 2025: Navigating Biosimilar Adoption and Operational Strategies in Oncology
July 14th 2025

ATOPP 2025: Navigating Biosimilar Adoption and Operational Strategies in Oncology

Laura R. Bobolts, PharmD, BCOP Alana Hippensteele, Lead Editor
ATOPP 2025: Pharmacy Innovation at the Intersection of EOM and Patient Access
July 10th 2025

ATOPP 2025: Pharmacy Innovation at the Intersection of EOM and Patient Access

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO Alana Hippensteele, Lead Editor